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BACKGROUND. Epidemiologic studies have suggested that environmental factors and diet
are important risk factors in the pathogenesis of prostate cancer. The N-acetyltransferases
(NAT) are important enzymes in activation and inactivation of various carcinogens, including
those found in well-cooked meat and cigarette smoke.
METHODS. We analyzed DNA samples from 146 prostate cancer patients and 174 healthy
men. We used PCR–RFLP method to analyze NAT1 and NAT2 polymorphisms.
RESULTS. We did not find statistically significant differences in NAT1 genotypes frequencies
between prostate cancer patients and control group. We observed an association of the slow
acetylator genotype,NAT2*6/NAT2*6with prostate cancer protection (P¼ 0.017; OR¼ 0.31, 95%
CI 0.11–0.84). Multivariate logistic regression analysis confirmed this association (0.030;
OR¼ 0.32, 95% CI 0.12–0.89).
CONCLUSIONS. Our results indicate a role of NAT2 polymorphisms in the carcinogenic
pathway of prostate cancer, specifically in a population of Southern Europe. Prostate 64: 246–
252, 2005. # 2005 Wiley-Liss, Inc.
KEY WORDS: NAT; polymorphisms; prostate cancer; acetylation; heterocyclic aromatic
amines
INTRODUCTION
Prostate cancer is one of the most common malig-
nancies in Western countries, being the second in cancer
incidence and the third in cancer mortality among men
in Portugal [1]. Several factors are associated with an
increased risk for prostate cancer. Epidemiologic studies
have suggested that environmental factors, including
ultra-violet radiation [2], smoking [3] and diet, including
meat and fat intake [4], are involved in the development
of prostate cancer. Many chemical and dietary carcino-
gens, especially heterocyclic amines derived from well-
cooked meat, seem to be involved in the pathogenesis of
prostate cancer [5].
The N-acetyltransferase (NAT) activity enrolls an
important step in both activation and inactivation of
numerous carcinogens, found for example in well-
cooked meat and cigarette smoke, respectively [6].
Therefore, the acetylator status may modify individual
response to various chemicals and thus individual
cancer susceptibility.
NATs are encoded by two genes, NAT1 and NAT2,
located in chromosome 8p 21.3-23.1 [7]. Both genes
are highly polymorphic. To date, 29 NAT2 alleles have
been identified [8]. Individuals who have two or more
NAT2 polymorphisms have a slow acetylator pheno-
type, individuals heterozygous for NAT2 polymorph-
isms have a rapid/intermediate acetylator phenotype,
and those who lacked NAT2 polymorphisms have a
rapid acetylator phenotype. Among all theNAT2 allelic
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variants, two (NAT2*5 and NAT2*6) were shown to
account for most of slow NAT2 acetylator genotypes
in Caucasian populations [9]. Previous studies have
found associations betweenNAT2 polymorphisms and
cancer risk [10–15].
Polymorphisms in NAT1 yield over 25 variant
alleles [8]. A common NAT1 allelic variant (NAT1*10)
is associated with increased catalytic activity (rapid
acetylator phenotype) [16]. This allelic variant has been
associated with increased risk to colorectal cancer,
compared with NAT1*4 homozygotes [17].
It has been reported that human prostate epithelial
cells metabolize potential carcinogens [17]. Further-
more, Wang et al. demonstrated the expression of
NAT1 and NAT2 transcripts in prostate cells [5].
Therefore, individual susceptibility to prostate cancer
may be modified by genetic polymorphisms in NAT1
and NAT2 enzymes. The aim of this study was to assess
the association between NAT1 and NAT2 polymorph-
isms and prostate cancer in a Portuguese population.
MATERIALSANDMETHODS
Patients
Consecutive patients (n¼ 146) with histologically
confirmed prostate cancer (median age 66 years) were
enrolled in this study between 1999 and 2000 from the
Department of Urology of the Portuguese Institute of
Oncology, Porto. Clinical characterization including
Gleason grade, disease status, age at diagnosis, and
prostate specific antigen (PSA) was obtained from
medical records. The control group consisted of 174
healthy individuals with no evidence of neoplastic
disease and a median age of 64 years. All participants
were Caucasian living in Porto district.
Approximately, 8 ml of venous blood was obtained
with a standard venipuncture technique using EDTA
tubes. DNA was extracted from the white blood cell
fraction from each study subject using a salting-out
protocol [18].
GenotypingofNAT1andNAT2Polymorphisms
For NAT1 genotype analysis we used a PCR–RFLP
method already described [19]. PCR conditions was
performed as follows: 100 ng of genomic DNA was
added to 0.25 mM of each primer, 0.2 mM of each dNTP,
1.5 mM MgCl2, 1 Taq buffer and 1U of Taq DNA-
polymerase to a final volume of 50 ml. Thirty five
cycles were performed, consisting of 948C (30 sec) for
denaturation, 458C (30 sec) for primer annealing, and
728C (45 sec) for primer extension. To differentiate
NAT1*4, NAT1*10, and NAT1*11 alleles, PCR product
was subjected to enzymatic digestion with Mbo II
enzyme. Restriction products were submitted to elec-
trophoresis in 4% Metaphor high resolution agarose
gel (Fig. 1). Digestion of NAT1*4 resulted in fragments
of 105, 71, 45, and 26 base pairs (bp), NAT1*10 in
fragments of 131, 75, 45, and 26 bp. The NAT1*11 allele
can be distinguished by observation of a 9 bp mobility
ship of the 131 bp band to a 122 bp band.
Genotyping for NAT2 was carried out using the
PCR–RFLP method [20]. The reactions of PCR con-
sisted of nearly 100 ng of genomic DNA, 1 mM of each
primer, 0.2 mM of each dNTP, 1.5 mM MgCl2, 1 Taq
buffer, and 1 U ofTaqDNA-polymerase to a final volume
of 50 ml. Thirty cycles were performed, consisting of
988C (30 sec) for denaturation, 628C (1 min) for primer
annealing, and 728C (1 min) for primer extension. After
amplification, 15 ml of PCR was digested with 20 U of
the Kpn I and Taq I restriction enzymes (positions 480
and 590) specific for the two different NAT2 allelic
variants to be screened (NAT2*5 and NAT2*6, respec-
tively). Restriction products were submitted to electro-
phoresis in 2% agarose gels. After digestion with Kpn I,
the 481-T (NAT2*5) and 481-C (NAT2*4) alleles were
visualized as fragments of 290 bp and 170 plus 120 bp,
respectively (Fig. 2A). The 590-A (NAT2*6) and 590-G
(NAT2*4) alleles were visualized as fragments of
290 and 230 plus 60 bp, respectively, after digestion
with Taq I (Fig. 2B).
Statistical Analysis
Analysis of data was performed using the program
SPSS for Windows (version 11.0). Chi-square analysis
was used to compare categorical variables. A 5% level
significance was used in the analysis. The odds ratio
Fig. 1. Mbo II RFLPs of the PCR products of the NAT1 alleles:
NAT1*4 alleles105, 71, 45, and 26 bp fragments,NAT1*10 allele
131, 75, 45, and 26 bp fragments andNAT1*11allele122, 75, 45, and
26bp fragments (M-DNAMolecularWeightMarkerVIII (RocheR)).
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(OR) and its 95% confidence interval (CI) was calcu-
lated as a measure of the association betweenNAT1 and
NAT2 genotypes and prostate cancer risk. Multivariate
logistic regression analysis was used to calculate the
adjusted OR and 95% CI for the influence of NAT
genotypes in the risk of prostate cancer, with adjust-
ment for age. We stratified the analysis according to
Gleason grade, disease status, age at diagnosis (median
age), and risk of disease progression (PSA higher than
10 mg/ml).
RESULTS
The frequencies of NAT1 genotypes in prostate
cancer cases and controls are shown in Table I. The
most common genotype was NAT1*4/NAT1*4 both in
cases (73.6%) and controls (75.2%). The NAT1*11 allele
was rare in controls (0.7%) and was not found in the
case groups. The frequency of NAT1*10 genotypes was
similar between cases and controls. There were not
statistically significant differences in NAT1 genotypes
between prostate cancer patients and healthy indivi-
duals.
The frequency of NAT2 genotypes in cases and
controls is shown in Table II. A statistically significant
difference was observed in the frequency of a NAT2
slow acetylator genotype, NAT2*6/NAT2*6, in prostate
cancer patients (3.4%) when compared with the control
group (10.3%) (P¼ 0.017; OR¼ 0.31, 95% CI 0.11–0.84).
Fig. 2. RFLPof thePCRproductsof theNAT2alleles.Kpn Irestriction(A)290bpfragmentNAT2*5allele;170plus120bpfragmentsNAT2*4
allele.Taq Irestriction(B)290bpfragmentNAT2*6allele;230bpplus60bpfragments(notvisualized)NAT2*4allele.(M100bpDNAladder
(GibcoBRLR)).




OR (95% CI)a Pn % n %
NAT1*4/NAT1*4 95 73.6 109 75.2 0.92 (0.53–1.58) 0.772
NAT1*4/NAT1*10 26 20.2 29 20.0 1.01 (0.55–1.82) 0.974
NAT1*10/NAT1*11 0 0 1 0.7 — 0.345
NAT1*10/NAT1*10 6 4.7 6 4.1 1.13 (0.35–3.59) 0.836
aOR were calculated from the ratio of the number of genotypes in interest versus all the other
genotypes.
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Multivariate logistic regression analysis confirmed this
association of NAT2*6/NAT2*6 genotype with prostate
cancer protection (P¼ 0.030; OR¼ 0.32, 95% CI 0.12–
0.89).
The association of NAT1 genotypes and clinico-
pathologic features of prostate cancer cases studied is
shown in Table III. No differences were found in the
frequencies of NAT1 genotypes regarding median age
of diagnosis, Gleason grade, disease status (advanced
or localized), and PSA levels. The same results were
obtained considering NAT2 genotypes (Table IV).
However, NAT2*6/NAT2*6 genotype frequency was
higher in prostate cancer patients with PSA levels lower
than 10 mg/ml, with suggestive statistical significance
(P¼ 0.054).
DISCUSSION
Prostate cancer appears to be dependent on the
interaction between environmental and genetics
factors, particularly dietary [21]. Several studies
reported that diet could alter steroid hormonal profile
and modify prostate cancer risk [22]. It has been
proposed that heterocyclic amines and polycyclic
hydrocarbons, which are produced by cooking meat
at high temperature, act as carcinogens in prostate
cancer carcinogenesis [5,17].
TABLE II. NAT2Genotype Frequencies in ProstateCancerCases andControlsWithOR
NAT2 genotype
Cases Controls
OR (95% CI)a Pn % n %
NAT2*4/NAT2*4 9 6.2 9 5.2 1.20 (0.46–3.11) 0.701
NAT2*4/NAT2*5 39 26.7 54 31.0 0.81 (0.49–1.31) 0.396
NAT2*4/NAT2*6 38 26.0 32 18.4 1.56 (0.091–2.66) 0.100
NAT2*5/NAT2*6 31 21.1 37 21.3 0.99 (0.058–1.70) 0.995
NAT2*5/NAT2*5 24 16.4 24 13.8 1.23 (0.66–2.27) 0.509
NAT2*6/NAT2*6 5 3.4 18 10.3 0.31 (0.11–0.84)b 0.017
aOR was calculated from the ratio of the number of genotypes in interest versus all the other
genotypes.
bAdjusted OR for age (logistic regression analysis): OR¼ 0.32, 95% CI 0.12–0.89; P¼ 0.03.
TABLE III. Association ofNAT1GenotypesWith theClinical and Pathological Features of
Prostate CancerCases Studied
NAT1 genotypes
NAT1*4/NAT1*4 NAT1*4/NAT1*10 NAT1*4/NAT1*11 NAT1*10/NAT1*10
n (%) P value n (%) P value n (%) P value n (%) P value
Median age
Age >66 40 (71.4) 13 (23.2) 1 (1.8) 2 (3.6)
0.607 0.448 0.682 0.472
Age 66 55 (75.3) 13 (17.8) 1 (1.4) 4 (5.5)
Gleason grade
Gleason >7 15 (78.9) 2 (10.5) 1 (5.3) 1 (5.3)
0.422 0.209 0.284 0.571
Gleason 7 77 (73.3) 23 (21.9) 1 (1.0) 4 (3.8)
PSA levels
PSA >10 64 (72.7) 19 (21.6) 2 (2.3) 3 (3.4)
0.741 0.964 0.527 0.202
PSA 10 27 (69.7) 3 (21.2) 0 (0.0) 3 (9.1)
Disease status
Advanced 44 (69.8) 13 (20.6) 1 (1.6) 5 (7.9)
0.338 0.894 0.740 0.094
Localized 51 (77.3) 13 (19.7) 1 (1.5) 1 (1.5)
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NAT enzymes are involved in the metabolism of
many carcinogens, including heterocyclic amines pre-
sent in cooking meat at high temperature [4,17]. Both
NAT1 and NAT2 are responsible for bothN-acetylation
(usually deactivation) and O-acetylation (usually acti-
vation) activities of aromatic and heterocyclic amines
carcinogens [23]. Another fact that should be taken
in consideration is that prostate cancer has been
associated with genetic alterations that include regions
of deletions on different chromosomal regions, such
as 8p 22-23 [24], which is the region of NAT genes [7].
Therefore, we hypothesise that NAT1 and NAT2 acety-
lator genotypes could be associated with susceptibility
to prostate cancer.
We observed no association between NAT1 poly-
morphism and prostate cancer susceptibility. Contro-
versial results have been reported regarding the role of
NAT1 and NAT2 in the susceptibility to prostate cancer
[10,25,26]. Previous reports presenting different results
[10,27], could be explained by the geographic differ-
ence between populations, since the frequencies of
NAT1 and NAT2 polymorphisms differ greatly with
ethnical characteristics [8]. In our results, the NAT2
slow acetylator genotypes, NAT2*6NAT2*6, was sig-
nificantly associated with prostate cancer (P¼ 0.030;
OR¼ 0.32, 95% CI 0.12–0.89). It is well known that this
slow acetylator genotype presents a lower enzyme
activity than rapid genotypes [28]. Individuals that
present this genotype show a lower capacity of meta-
bolizing carcinogens. Many N-hydroxy heterocyclic
amines, carcinogens are metabolically activated to a
great extent by NAT2 [6,29], and these carcinogens
seem to be of potential carcinogenicity to human
prostate epithelial cells [5,17]. Therefore, carriers of
NAT2*6NAT2*6 genotype have a lower capacity to
activate carcinogens. This is consistent with the pro-
tective effect of NAT2*6/NAT2*6 genotype to prostate
cancer that we reported in our study. Furthermore,
we found that NAT2*6/NAT2*6 genotype is over-
represented in the group of prostate cancer patients
with PSA levels lower than 10 mg/ml in comparison
with patients with PSA levels higher than 10 mg/ml.
This reinforces a role for NAT2*6NAT2*6 genotype in
the prostate cancer biology.
Several reports have shown the contribution of
genetic polymorphisms to the risk of prostate cancer
[30–35]. Our study brings new reports that may help to
clarify the function of NAT polymorphisms in prostate
cancer development. Our results suggest a role ofNAT2
polymorphisms in the carcinogenic pathway of pros-
tate cancer in a population of Southern Europe. Future
studies concerning the association of NAT genotypes
and environmental or lifestyle factors (e.g., diet) will
be important to elucidate the real meaning of NAT
polymorphisms in the susceptibility to prostate cancer.
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